Back

Outlook, panel discussion and Q&A

19 May 2025 (13:13 - 13:28)
Organised by: Logo
Congress Presentation Part of: Does aldosterone synthase inhibition hold a key to transforming cardiorenal care? Aldosterone Antagonists HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

6 More presentations in this session

Presentation thumbnail
Welcome and introductions
Slides
Presentation thumbnail
The integrated nature of cardiorenal metabolic health
Professor L. Lund (Stockholm, SE)
Slides
Presentation thumbnail
The role of aldosterone and its part in cardiorenal disease
Doctor M. Costanzo (Naperville, US)
Slides
Presentation thumbnail
Insights from the vicadrostat phase 2 study and implications for further clinical development
Doctor R. Mentz (Durham, US)
Slides
Presentation thumbnail
Aldosterone synthase inhibition and the future CRM treatment landscape
Professor J. Butler (Dallas, US)
Slides

Access the full session

Session thumbnail
Does aldosterone synthase inhibition hold a key to transforming cardiorenal care?
Video

The Event

Event poster

Heart Failure 2025

19 May 2025 13:13 CET
You may be interested in
thumbnail
Congress Session
What’s on the horizon in heart failure: precision medicine and tailored treatment
18 May 2025
thumbnail
Congress Presentation
Breaking through: CETP inhibitors and the future of lipid therapy
29 August 2025
thumbnail
Congress Session
Obesity as a cardiovascular disease: integrated management
3 April 2025
thumbnail
Congress Presentation
Longevity: the next health-wealth challenge
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources